Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Fig. 2

Distribution of RET fusions. a RET fusions identified by targeted NGS in the total patient cohort (N = 451). b A schematic demonstration of functional domains in KIF5B-RET and CCDC6-RET fusions identified in the study cohort. Descriptions on the right indicate exons in the partner gene and RET gene. KIF5B-RET fusion proteins contain the kinesin motor domain (orange), the coiled coil domain (blue) from KIF5B, and the kinase domain (pink) of RET, or the transmembrane domain (grey) and the kinase domain of RET. CCDC6-RET fusions contain the coiled coil domain (yellow) of CCDC6 and the kinase domain of RET, or the transmembrane domain and the kinase domain of RET. c, d Distribution of RET fusion partner genes in baseline (c) and acquired (d) RET+ patients

Back to article page